Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients (CODYS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04522037 |
Recruitment Status :
Recruiting
First Posted : August 21, 2020
Last Update Posted : August 21, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Morphine is used in the treatment of dyspnea and polypnea with a proven benefit on the improvement of these symptoms, both etiologically and symptomatically. This medication is used in particular in palliative care for this type of symptom.
The Sars CoV2 viral pneumonia table can lead to respiratory distress. In patients with moderate to severe impairment without goal of resuscitation (level of care 3 and 4), the introduction of morphine may sometimes be necessary to relieve respiratory symptoms. These also lead to major exhaustion which can worsen the clinical picture. However, the prescription of morphine is not systematic in front of a respiratory distress table.
The investigators hypothesized that early treatment with morphine lead to a better management of dyspnea, quality of live and survival in COVID-19 positive participants patients when there is not resuscitation objective management (level of care 3 and 4).
The objective is to measure the efficacy of morphine in the early management of dyspnea, quality of life and survival in COVID-19 positive participants patients treated in the Hospices Civils of Lyon during COVID-19 pandemic.
Condition or disease | Intervention/treatment |
---|---|
Patients Hospitalized in the Hospices Civils of Lyon COVID-19 Disease Moderate to Severe Dyspnea Without Resuscitation Objective Management | Other: No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups |
Study Type : | Observational |
Estimated Enrollment : | 200 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon |
Actual Study Start Date : | June 1, 2020 |
Estimated Primary Completion Date : | September 2020 |
Estimated Study Completion Date : | February 2021 |

Group/Cohort | Intervention/treatment |
---|---|
interventional group
patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 receiving morphinic treatment for COVID-19 disease dyspnea.
|
Other: No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups
Respiratory rate is analyzed with the scope (approved by the French national medical authorities) |
control group
patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 not receiving morphinic treatment for COVID-19 disease dyspnea.
|
Other: No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups
Respiratory rate is analyzed with the scope (approved by the French national medical authorities) |
- Title : Reduction of respiratory rate between Hour 0 and Hour 12 at initiation of morphine treatment [ Time Frame: Hour 0 and Hour 12 after initiation of morphinic treatment ]The respiratory rate is analyzed at Hour 0 and Hour 12 by a scope.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age over 18 years.
- Having had a Covid-19 respiratory disease confirmed by PCR or TDM or anamnestic criterion for patients living in communities for the elderly (respiratory symptomatology suggestive and at least 3 cases confirmed in the living environment).
- Having had respiratory severity criteria: respiratory distress syndrome including FR> 25 / min and oxygen-demand> 4 L / min to maintain a SpO2> 90% at inclusion.
- Having had a defined level of care after collegial discussion notified in the file rejecting the external cardiac massage and admission to the intensive care unit (Level 3 and 4 on the protocols of the Hospices Civils de Lyon).
- Collection of non-opposition
Exclusion Criteria:
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04522037
Contact: Myriam Legenne | 4 72 07 25 79 ext +33 | myriam.legenne@chu-lyon.fr |
France | |
Hôpital de la Croix Rousse / GHN | Recruiting |
Lyon, France, 69004 | |
Contact: Myriam Legenne, Dr 4 72 07 25 79 ext +33 myriam.legenne@chu-lyon.fr | |
Hôpital Edouard Herriot | Recruiting |
Lyon, France, 69008 | |
Contact: Sophie Francioni, Dr 4 72 11 96 08 ext +33 sophie.francioni@chu-lyon.fr | |
Hôpital Lyon Sud | Recruiting |
Pierre-Bénite, France, 69445 | |
Contact: Guillaume Economos, Dr 4 78 86 41 48 ext +33 guillaume.economos@chu-lyon.fr |
Responsible Party: | Hospices Civils de Lyon |
ClinicalTrials.gov Identifier: | NCT04522037 |
Other Study ID Numbers: |
CODYS_2020 |
First Posted: | August 21, 2020 Key Record Dates |
Last Update Posted: | August 21, 2020 |
Last Verified: | July 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 disease level of care 3 and 4 morphinic treatment dyspnea |
Dyspnea Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory Morphine Analgesics, Opioid |
Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents |